Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1994198 | 0.98 | PDE2A (0.43) | PDE2ASCN5ACYP1A2SCN1ASCN2A | |
| SCHEMBL12196281 | 0.81 | MEN1 (0.36) | PDE2ASCN5AMEN1KMT2A | |
| SCHEMBL14956276 | 0.73 | PDE2A (0.39) | PDE2ASCN5ACYP1A2ALDH1A1 | |
| SCHEMBL750920 | 0.71 | KDM4E (0.50) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL18879057 | 0.69 | RET (0.42) | PDE2A | |
| SCHEMBL2978953 | 0.69 | PDE2A (0.38) | PDE2ALMNAALDH1A1MEN1KMT2A | |
| SCHEMBL21917175 | 0.69 | PDE2A (0.35) | PDE2AALDH1A1MEN1KMT2A | |
| SCHEMBL22323377 | 0.69 | PDE2A (0.35) | PDE2A | |
| SCHEMBL21713333 | 0.67 | SCN5A (0.41) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL5935853 | 0.67 | PDE2A (0.34) | PDE2ACYP1A2LMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109761988-B | Preparation method of sitagliptin serving as medicine for treating diabetes | 深圳市第二人民医院 | 2021-07-23 | — | — | CN | claimed |
| CN-115976132-A | Preparation method of sitagliptin and analogs thereof | 浙江永太手心医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115728411-A | Method for analyzing genotoxic impurity TTTP-NO in sitagliptin phosphate | 乳源东阳光药业有限公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-111793012-B | Novel sitagliptin intermediate and preparation method thereof | 尚科生物医药（上海）有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-109761988-B | Preparation method of sitagliptin serving as medicine for treating diabetes | 深圳市第二人民医院 | 2021-07-23 | — | — | CN | disclosed |
| US-20210171530-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-10 | — | — | US | disclosed |
| CN-111793012-A | Novel sitagliptin intermediate and preparation method thereof | 尚科生物医药（上海）有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-20200206221-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20170348309-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
| US-20070208010-A1 | Fused Triazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME CORP. | 2007-09-06 | — | — | US | disclosed |
| EP-1583534-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1412357-B1 | BETA-AMINO TETRAHYDROIMIDAZO(1,2-A)PYRAZINES AND TETRAHYDROTRIAZOLO(4,3-A)PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060052382-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1625847-A1 | Pharmaceutical composition comprising a tetrahydrotriazolo[4,3-a]pyrazine | Merck & Co., Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1583534-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040167133-A1 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2004-08-26 | — | — | US | disclosed |
| WO-2004058266-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206221-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | PDE2A 778/4885SCN5A 1294/4885CYP1A2 1250/4885 |
| US-20060052382-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | PDE2A 828/4885SCN5A 1281/4885CYP1A2 1351/4885 |
| US-20040167133-A1 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | PDE2A 748/4885SCN5A 536/4885CYP1A2 436/4885 |
| US-20070208010-A1 | Fused Triazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | PDE2A 671/4885SCN5A 1626/4885CYP1A2 681/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | PDE2A 2119/4885SCN5A 1059/4885CYP1A2 3169/4885 |
| US-20210171530-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | PDE2A 1439/4885SCN5A 5/4885CYP1A2 2873/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | PDE2A 1031/4885SCN5A 1886/4885CYP1A2 3844/4885 |
| US-20170348309-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | PDE2A 778/4885SCN5A 1294/4885CYP1A2 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.